IQVIA HOLDINGS INC.

(IQV)
  Report
Delayed Nyse  -  05/27 04:03:38 pm EDT
220.50 USD   +6.15%
05/25IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022
BU
05/24WALL STREET STOCK EXCHANGE : Snap cut the rally short
05/24ANALYST RECOMMENDATIONS : Chubb, Glencore, Metlife, Moonpig, Salesforce...
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

12/06/2021 | 07:00am EDT

ASLAN Pharmaceuticals announced the appointment of IQVIA Biotech. IQVIA Biotech will provide patient recruitment, clinical monitoring, medical writing and biostatistics for ASLAN?s upcoming 300-patient Phase 2b trial of ASLAN004 in adults with moderate-to-severe atopic dermatitis. IQVIA Biotech will work closely with ASLAN?s management to oversee clinical operations and the recruitment of patients across sites in the United States, Canada, Europe and Asia. IQVIA Biotech is also positioned to collaborate with ASLAN?s clinical operations team on the future development plans for ASLAN003 in inflammatory bowel disease (IBD), with clinical trials commencing early next year. Enrollment of the first patient in the ASLAN004 Phase 2b trial is expected in the fourth quarter of 2021.


© S&P Capital IQ 2021
All news about IQVIA HOLDINGS INC.
05/25IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022
BU
05/24WALL STREET STOCK EXCHANGE : Snap cut the rally short
05/24ANALYST RECOMMENDATIONS : Chubb, Glencore, Metlife, Moonpig, Salesforce...
05/24Guggenheim Starts IQVIA Holdings at Buy With $244 Price Target
MT
05/05TikoMed AB and IQVIA Announce Strategic Collaboration for the Development of TikoMed's ..
CI
05/04TRANSCRIPT : IQVIA Holdings Inc. - Special Call
CI
04/29IQVIA Holdings Shares Rise Midday Following Piper Upgrade, Target Increase
MT
04/29Piper Sandler Lifts IQVIA Holdings to Overweight From Neutral, Price Target to $255 Fro..
MT
04/28IQVIA HOLDINGS INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
04/28Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 20..
CI
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 14 622 M - -
Net income 2022 1 303 M - -
Net Debt 2022 10 199 M - -
P/E ratio 2022 32,6x
Yield 2022 -
Capitalization 41 736 M 41 736 M -
EV / Sales 2022 3,55x
EV / Sales 2023 3,17x
Nbr of Employees 82 000
Free-Float 73,3%
Chart IQVIA HOLDINGS INC.
Duration : Period :
Iqvia Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 220,50 $
Average target price 265,59 $
Spread / Average Target 20,4%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
Jeffrey A. Spaeder Chief Medical & Scientific Officer
Costa Panagos President-Research & Development Solutions
Sector and Competitors
1st jan.Capi. (M$)
IQVIA HOLDINGS INC.-21.85%41 736
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478
CELLTRION, INC.-21.21%17 245